Tadalafil to help breathing in COPD with pulmonary hypertension
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This Phase 2 study tests whether tadalafil can improve breathlessness in people with COPD and pulmonary hypertension (high blood pressure in the lungs). It may help you breathe more easily if your symptoms are driven by this specific lung circulation problem.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have COPD confirmed by breathing test results (FEV1/FVC below 70%) or emphysema on a chest CT scan
- You have pulmonary hypertension shown on recent tests (CT size, echo blood-pressure estimates, or a right-heart catheter test)
- You feel very short of breath, scoring at least 20 on a breathing-questions form
- You take at least one long-acting breathing medicine (a long-acting bronchodilator) for 4 weeks or more
- You’re between ages 35 and 89 (and you’re able to follow study visits and procedures)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether tadalafil can improve outcomes for people with severe pulmonary hypertension caused by COPD (chronic lung disease). It compares how you do with tadalafil versus standard care, focusing on breathing symptoms and how well your heart and lungs cope.
This Phase 2 trial tests whether sildenafil tablets can improve exercise ability, shortness of breath, and heart-lung function in people with COPD. It also compares against people without COPD to better understand how sildenafil affects breathing tests.
This study tests an oral tablet called RSS0343 for people with moderate to severe COPD. It aims to see if the tablet can improve lung function and reduce flare-ups when added to your current breathing treatments.
This study tests a new inhaled powder medicine (TQC3927) against an existing combination inhaler for treating COPD, a lung disease that makes breathing difficult. The goal is to see if the new medicine works as well or better and is safe for people with COPD.
This trial tests an inhaled medicine (TPIP) for people with both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug helps improve exercise ability and symptoms.
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.